This study is being done to test whether a drug called baricitinib, which blocks specific causes of inflammation, affects HIV-1 viral rebound and viral load levels after HIV treatment is discontinued. Researchers will test the effects of continuing baricitinib in people with HIV before and after discontinuing their antiretroviral therapy. This drug is approved by the Food and Drug Administration (FDA) for other diseases; it is not approved for the treatment of HIV-1. The study team will also investigate any side effects associated with the drug.
Phase:
PHASE2
Details
Lead Sponsor:
Emory University
Collaborator:
Eli Lilly and Company
Treatments:
Antiretroviral Therapy, Highly Active baricitinib Standard of Care